Simon Pedder

Simon C.
Pedder was the founder of Chelsea Therapeutics International Ltd., founded in 2005, where the titles held included President, Chief Executive Officer & Director from 2005 to 2012.
Current jobs include Chief Executive Officer at Nirogy Therapeutics, Inc. since 2022; Executive Chairman at Adaptin Bio, Inc. starting in 2025; and Director roles at Eboo Pharmaceuticals, Inc., Ballantyne Therapeutics, Inc., and Atlantic Research Group, Inc. Former jobs include President & Chief Executive Officer at Ivory Capital Corp.
from 2004 to 2005; President & Chief Executive Officer at Chelsea Therapeutics, Inc. from 2004 to 2012; Chief Executive Officer & Director at Novelos Therapeutics, Inc. from 2013 to 2014; President, Chief Executive Officer & Director at Cellectar Biosciences, Inc. from 2014 to 2015; Independent Director at Oncotelic Therapeutics, Inc. from 2016 to 2019; Independent Director at Delcath Systems, Inc. from 2017 to 2019; President & Director at Avalo Therapeutics, Inc. in 2020; Vice President at Oncology Pharma, Inc.; Chief Business & Strategy Officer-Proprietary at Athenex, Inc. from 2016 to 2021; Vice President-Pharmaceutical Business & Oncology at Hoffmann-La Roche, Inc.; Vice President-Drug Development at Shearwater Corp.
from 2001 to 2002; and Member at the University of Saskatchewan College of Medicine.
Education includes graduate degree from Concordia University, undergraduate degree from The University of Waterloo, and doctorate from the University of Saskatchewan College of Medicine.